NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free GLUE Stock Alerts $5.54 +0.04 (+0.73%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$5.50▼$6.0550-Day Range$4.76▼$8.4652-Week Range$2.44▼$8.84Volume76,390 shsAverage Volume148,252 shsMarket Capitalization$277.83 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside98.6% Upside$11.00 Price TargetShort InterestBearish5.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.25) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.99 out of 5 starsMedical Sector561st out of 909 stocksBiological Products, Except Diagnostic Industry95th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.31% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 8.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 2.9 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.MarketBeat Follows4 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.25) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesApril 16, 2024 | americanbankingnews.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 8.9% March 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 19, 2024 | finance.yahoo.comWall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should KnowMarch 16, 2024 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comIs Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?March 14, 2024 | markets.businessinsider.comPromising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa TherapeuticsMarch 14, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 14, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | benzinga.comMonte Rosa Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorMarch 1, 2024 | morningstar.comMonte Rosa Therapeutics Inc GLUEFebruary 24, 2024 | msn.comMonte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32February 23, 2024 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE), Analyst Ratings, Price Targets, PredictionsFebruary 15, 2024 | msn.comMonte Rosa draws bullish view at Wedbush on protein degradationFebruary 15, 2024 | msn.comMonte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: AnalystJanuary 16, 2024 | fool.com3 Incredible Growth Stocks That Could Soar in 2024, According to Wall StreetJanuary 8, 2024 | finance.yahoo.comMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024January 3, 2024 | finance.yahoo.comMonte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Earnings Dates and Earning CallsDecember 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Dividends: History, Yield and DatesNovember 21, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)November 9, 2023 | benzinga.comMonte Rosa Therapeutics: Q3 Earnings InsightsSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+98.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.93% Return on Assets-47.35% Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick Ratio5.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.55Miscellaneous Outstanding Shares50,150,000Free Float47,492,000Market Cap$277.83 million OptionableOptionable Beta1.45 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsInvivydNASDAQ:IVVDMetagenomiNASDAQ:MGXBlack Diamond TherapeuticsNASDAQ:BDTXAnavex Life SciencesNASDAQ:AVXLFennec PharmaceuticalsNASDAQ:FENCView All CompetitorsInstitutional OwnershipTower Research Capital LLC TRC Sold 9,367 shares on 2/13/2024Ownership: 0.016%Simplex Trading LLCBought 14,600 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions Should I buy or sell Monte Rosa Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks. What is Monte Rosa Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 12 month target prices for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts. How have GLUE shares performed in 2024? Monte Rosa Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, GLUE stock has decreased by 1.9% and is now trading at $5.54. View the best growth stocks for 2024 here. Are investors shorting Monte Rosa Therapeutics? Monte Rosa Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,680,000 shares, a decline of 8.2% from the March 15th total of 1,830,000 shares. Based on an average daily volume of 150,300 shares, the days-to-cover ratio is currently 11.2 days. Approximately 5.3% of the shares of the company are sold short. View Monte Rosa Therapeutics' Short Interest. When is Monte Rosa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GLUE earnings forecast. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, March, 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.01. What ETFs hold Monte Rosa Therapeutics' stock? ETFs with the largest weight of Monte Rosa Therapeutics (NASDAQ:GLUE) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
